Alpha Paradigm Partners’s Maravai LifeSciences MRVI Stock Holding History

Alpha Paradigm Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,181	Closed	-$119K	–	577
2022 Q2	$119K	Buy	+4,181	New	+$132K	0.05%	381
2022 Q1	–	Sell	-461	Closed	-$19K	–	636
2021 Q4	$19K	Buy	+461	New	+$18.7K	0.01%	504
2021 Q3	–	Sell	-4,742	Closed	-$198K	–	616
2021 Q2	$198K	Buy	+4,742	New	+$184K	0.07%	353

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Alpha Paradigm Partners's MRVI Position: Q3 2022 in Review

Alpha Paradigm Partners sold out of Maravai LifeSciences (MRVI) in Q3 2022, closing a stake of 4,181 shares — an estimated $119K sold.

Alpha Paradigm Partners first reported a position in MRVI in Q2 2021 and held it in 3 quarters. The position peaked at $198K in Q2 2021. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2022.

Alpha Paradigm Partners reported no remaining Maravai LifeSciences position as of Q3 2022 after selling out during the quarter.
Alpha Paradigm Partners sold 4,181 Maravai LifeSciences shares in Q3 2022, an estimated $119K.
Alpha Paradigm Partners first reported a position in Maravai LifeSciences in Q2 2021 and held it in 3 quarters.
Alpha Paradigm Partners's Maravai LifeSciences position peaked at $198K in Q2 2021.
202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2022.

Based on Alpha Paradigm Partners's 13F filing for Q3 2022, filed 15 Nov 2022.